Gesmundo, Nathan http://orcid.org/0000-0003-2882-192X
Dykstra, Kevin
Douthwaite, James L. http://orcid.org/0000-0002-4478-9010
Kao, Yu-Ting http://orcid.org/0000-0001-5804-2471
Zhao, Ruheng http://orcid.org/0000-0002-0791-8020
Mahjour, Babak http://orcid.org/0000-0002-8225-6514
Ferguson, Ron
Dreher, Spencer
Sauvagnat, Bérengère
Saurí, Josep
Cernak, Tim http://orcid.org/0000-0001-5407-0643
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01GM144471)
National Defense Medical Center of Taiwan Fellowship
American Chemical Society (MEDI Division Predoctoral Fellowship)
Article History
Received: 17 August 2022
Accepted: 22 May 2023
First Online: 22 June 2023
Competing interests
: The majority of experimental work was performed at Merck & Co., Inc., Rahway, NJ, USA. The Cernak Lab at University of Michigan has received research funding or in-kind donations from MilliporeSigma, Relay Therapeutics, Janssen Therapeutics, Entos, Inc., SPT Labtech and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. T.C. is a former employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, holds equity in Scorpion Therapeutics, and is a cofounder and equity holder of Entos, Inc. The other authors declare no competing interests.